Journal
ANNALS OF SURGICAL TREATMENT AND RESEARCH
Volume 101, Issue 1, Pages 20-27Publisher
KOREAN SURGICAL SOCIETY
DOI: 10.4174/astr.2021.101.1.20
Keywords
Angioplasty; Mortality; Paclitaxel; Peripheral arterial occlusive disease; Stents
Categories
Funding
- Medtronic Korea
- Korean National Health Insurance Service [NHIS-2019-1-134]
Ask authors/readers for more resources
This study based on Korea national administrative claims data found that drug-coated devices used in femoropopliteal artery revascularization did not increase all-cause mortality risk. Adjusted hazard ratios showed that drug-coated devices were associated with decreased all-cause mortality risk.
Purpose: Drug-coated devices have been widely accepted as one of the most promising therapies for femoropopliteal artery revascularization. A recent meta-analysis showed increased mortality in patients treated with drug-coated devices. We sought to examine the association between mortality and drug-coated devices after the treatment of the femoropopliteal artery based on the Korea national administrative claims data. Methods: In the National Health Insurance Service database from August 2015 to December 2017, we identified patients with femoropopliteal artery revascularization using percutaneous transluminal angioplasty (PTA), bare metal stents (BMS), drug-coated balloon (DCB), or drug-eluting stents (DES). Kaplan-Meier methods were used to estimate the survival among devices, and log-rank tests were used to evaluate differences between groups. Adjusted hazard ratios (aHRs) were computed using the inverse probability of treatment weightings (IPTW). Results: There were 1,724 patients (mean age, 70.9 +/- 10.7 years; male, 1,350 [78.3%]) included in the analysis. The median follow-up period was 552 days (interquartile range, 404-688 days). There was a difference in IPTW-adjusted mortality risk among device types (26.3% in PTA, 22.1% in BMS, 17.7% in DCB, and 17.8% in DES; P = 0.004). IPTW-adjusted Cox proportional hazard analysis showed that drug-coated devices were associated with decreased all-cause mortality risk (aHR, 0.70; 95% confidence interval, 0.58-0.86). Conclusion: Our real-world analysis showed that there was no evidence of increased all-cause mortality after femoropopliteal artery revascularization with drug-coated devices compared with non-drug-coated devices. [Ann Surg Treat Res 2021;101(1):20-27]
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available